Novonesis and Novo Nordisk have entered a research partnership to explore how the gut microbiome can help preserve metabolic health and reduce the risk of obesity and related diseases. The collaboration will develop and test synbiotic food supplements, combining probiotics and prebiotics, to improve markers such as blood glucose, cholesterol, and inflammation. Researchers will also investigate new biomarkers and use deep phenotyping to measure outcomes, aiming to build predictive tools for long-term health. Leaders from both organizations emphasize that this work reflects a shared commitment to prevention, innovative biosolutions, and sustainable strategies against the global rise of obesity.
Reaction from across healthcare and related fields demonstrates the perceived importance of this work. Commentators highlighted the potential to move “beyond treatment and into early risk prediction and personalised prevention”, and praised the collaboration as an example of leaders “shaping the next wave of health-focused biosolutions”. Others noted the broader relevance of gut-brain axis research and how scalable solutions could change the trajectory of obesity, diabetes, and related conditions.
By combining expertise in biosolutions and metabolic health, Novonesis and Novo Nordisk aim to deliver meaningful progress in addressing obesity and related diseases.
Sources
